Auxilium Biotechnologies, Inc. is structured around development of a second-generation drug-delivery medical device more effectively to treat people who have sustained traumatic peripheral nerve injury. The firm's Gen 1.0 NeuroSpan Bridge is a biomimetic nerve regeneration device designed to guide and accelerate nerve regeneration - effectively eliminating the need for a patient to sacrifice a nerve in the leg to repair a nerve in the arm or face. Auxilium is reported as using the firm's expertise in fast, high-resolution 3D-printing to adapt its proprietary platform to a Gen 2.0 3D-print device in microgravity by adding novel drug delivery nanoparticles with the potential to substantially accelerate regeneration and improve functional outcomes for people on Earth.
